Education
About Us
Working with TipRanks
Follow Us
Scandion Oncology A/S (DE:8VY)
FRANKFURT:8VY
8VY Stock Chart & Stats
Day’s Range― - ―
52-Week Range<€0.01 - €0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€225.28K
Enterprise Value-€1.87M
Total Cash (Recent Filing)kr26.52M
Total Debt (Recent Filing)kr499.00K
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
May 22, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding234,761,410
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1635.97
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
8VY FAQ
What was Scandion Oncology A/S’s price range in the past 12 months?
Scandion Oncology A/S lowest stock price was <€0.01 and its highest was €0.06 in the past 12 months.
What is Scandion Oncology A/S’s market cap?
Scandion Oncology A/S’s market cap is €225.28K.
When is Scandion Oncology A/S’s upcoming earnings report date?
Scandion Oncology A/S’s upcoming earnings report date is May 22, 2025 which is in 25 days.
How were Scandion Oncology A/S’s earnings last quarter?
Scandion Oncology A/S released its earnings results on Mar 12, 2025. The company reported -€0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.009.
Is Scandion Oncology A/S overvalued?
According to Wall Street analysts Scandion Oncology A/S’s price is currently Overvalued.
Does Scandion Oncology A/S pay dividends?
Scandion Oncology A/S does not currently pay dividends.
What is Scandion Oncology A/S’s EPS estimate?
Scandion Oncology A/S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandion Oncology A/S have?
Scandion Oncology A/S has 234,761,410 shares outstanding.
What happened to Scandion Oncology A/S’s price movement after its last earnings report?
Scandion Oncology A/S reported an EPS of -€0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Scandion Oncology A/S?
Currently, no hedge funds are holding shares in DE:8VY
---
Company Description
Scandion Oncology A/S
Scandion Oncology A/S is a biotechnology company with the mission to address one of the most important challenges in modern oncology - the effective treatment of cancer which has developed resistance towards existing cancer medicine. Its first-in-class lead compound, SCO-101, is an add-on to chemotherapy and is currently in clinical phase I and II studies in cancer patients. The company also has several preclinical programs to build a broader pipeline of drugs for the treatment of drug-resistant cancer diseases.
---
LIDDS AB
―
Xintela AB
―
Lipigon Pharmaceuticals AB
―
CombiGene AB
―
Sprint Bioscience AB
―
---